A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

Open-Label Randomized Two-Way Crossover Pilot Study To Estimate The Effects Of Inhaled Versus IV Infusion Of Human Insulin With Regards To Glucose Disposal In Subjects With Type 1 Diabetes Mellitus

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00287066

Enrollment

Registered

2006-02-06

Start date

2006-02-28

Completion date

2007-03-31

Last updated

2008-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Brief summary

To assess the impact of inhalation of insulin on glucose disposition in patients with type 1 diabetes

Detailed description

The study was terminated on Oct. 28, 2007. The protocol was undergoing implementation and methodological issues with major revisions that qualified this trial as a new trial. Pfizer decided to cancel new trials because of the decision to withdraw Exubera due to lack of market performance and not for safety reasons.

Interventions

DRUGInhaled Human Insulin

DRUGRegular Human Insulin

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Diabetes mellitus Type 1

Exclusion criteria

* Asthma, COPD * Smoking

Design outcomes

Primary

Measure	Time frame
18F-labeled glucose uptake in muscle	—

Secondary

Measure	Time frame
Glucose turnover overnight Insulin pharmacokinetics	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026